Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

GW Pharmaceuticals seizure drug aces phase three trial

GW Pharmaceuticals expects to file a new drug application to the FDA in the first half of next year.
A dying child
Lennox-Gastaut syndrome is a severe form of childhood epilepsy

GW Pharmaceuticals plc (NASDAQ:GWPH, LON:GWP) cannabinoid drug Epidiolex has achieved primary endpoint in treating Lennox-Gastaut syndrome - a severe form of childhood epilepsy - speeding through phase three trials.

Back in June, the group’s first pivotal phase three study of Epidiolex for the treatment of seizures in connection with the syndrome revealed favourable results. And then in March, the group released positive results in connection with Dravet syndrome.

Epidiolex was well tolerated during the trial period. The adverse pattern of events was in line with the previously reported two Phase 3 studies.

GW Pharmaceuticals expects to file a new drug application to the FDA in the first half of next year.

 "We feel a tremendous sense of urgency to stop seizures, and believe that the pursuit of new therapies offers hope to individuals who have no currently available therapy to effectively stop their seizures,” said chief executive Philip Gattone.

Shares trading on the London Stock Exchange rose 11% to 775.5p. 



Register here to be notified of future GWP Company articles
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

brokerreport.jpg
January 25 2017
Analyst Vadim Alexandre, of the company’s broker Northland Capital, said Wednesday’s update provided “better visibility” on the trial timetable.
blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
Dimerix: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Kathy Harrison talked pending milestone news with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use